Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 716 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cystic Fibrosis Lung Clear all
Completed No phase listed Observational Accepts healthy volunteers

Clinical Evaluation of NeoPlex4 Assay and NeoPlex System

NCT01488721
View directory record Official record
Conditions
Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Luminex Corporation
Industry
Eligibility
1 Day to 7 Days
Enrollment
7,462 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Albany, New York • Nashville, Tennessee • Taylorsville, Utah
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Oct 19, 2026, 9:12 PM EDT
Terminated Phase 1 Interventional

IGF-1 Therapy in Patients With Cystic Fibrosis

NCT00566241
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
recombinant human IGF-1, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00112359
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg three times a day (TID), Placebo three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
40
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2011 · Synced Oct 19, 2026, 9:12 PM EDT
Terminated Phase 1 Interventional Results available

Growth Hormone Therapy for Wasting in Cystic Fibrosis

NCT00803179
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nutropin AQ
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Not applicable Interventional

Gaming Console Home-Based Exercise for Adults With Cystic Fibrosis

NCT02277860
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multilevel Models of Therapeutic Response in the Lungs

NCT02947126
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hypertonic Saline, Isotonic Saline, Indium-DTPA, Technetium Sulfur Colloid
Drug
Lead sponsor
Tim Corcoran
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Phase 2 Interventional Results available

28 Day Repeat Dose in Cystic Fibrosis Patients

NCT00903201
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
SB656933, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

NCT02347657
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661 Plus Ivacaftor Combination, Ivacaftor, VX-661 Plus Ivacaftor Combination Placebo, Ivacaftor placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
27
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Phase 3 Interventional

Growth Hormone Use in Cystic Fibrosis - a Multicenter Study

NCT00005112
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Human recombinant growth hormone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Not applicable Interventional Results available

Ketone Supplementation in Cystic Fibrosis

NCT04938726
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ketone Monoester
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Not applicable Interventional Results available

Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis

NCT01031706
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hypertonic Saline, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 12 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Phase 1 Interventional Results available

Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis

NCT01094704
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
sodium chloride (7%)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 19, 2026, 9:12 PM EDT
Terminated Early Phase 1 Interventional

19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation

NCT03497117
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lung Clearance Index, MRI with PFP
Device · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)

NCT00690820
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions
Pancrelipase Delayed Release, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
7 Years to 11 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
10
States / cities
Iowa City, Iowa • Louisville, Kentucky • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2010 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

NCT05033080
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Phase 2 Interventional Results available

NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients

NCT00809094
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
N-acetylcysteine (NAC), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
7 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 19, 2026, 9:12 PM EDT
Completed No phase listed Observational Results available

IL-17 Neutrophils in CF Lung Inflammation

NCT02025829
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

NCT01705145
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years to 5 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
16
States / cities
Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

NCT02390219
View directory record Official record
Conditions
Cystic Fibrosis, Advanced Lung Disease
Interventions
Lumacaftor, Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Denver, Colorado • Tampa, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

NCT01685801
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo-matched-to-ivacaftor tablet
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 19, 2026, 9:12 PM EDT
Recruiting Not applicable Interventional

ACT With CF Self-Help Toolkit

NCT07436351
View directory record Official record
Conditions
Cystic Fibrosis (CF), Depressive and Anxiety Disorders, Psychological Flexibility
Interventions
ACT with CF Self-Help Toolkit, Waitlist
Behavioral · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Not applicable Interventional Results available

Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes

NCT03258853
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
10 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 19, 2026, 9:12 PM EDT
Not listed No phase listed Observational

Impact of Triple Combination CFTR Therapy on Sinus Disease.

NCT04056702
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Elexacaftor-tezacaftor-ivacaftor exposure
Drug
Lead sponsor
Jennifer Taylor-Cousar
Other
Eligibility
18 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 19, 2026, 9:12 PM EDT
Completed Phase 3 Interventional Results available

Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)

NCT02139306
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ataluren (PTC124®), Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Birmingham, Alabama • Mobile, Alabama • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 19, 2026, 9:12 PM EDT